2022 Q3 Form 10-K Financial Statement

#000101738623000022 Filed on January 17, 2023

View on sec.gov

Income Statement

Concept 2022 Q3 2022 2021
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.88K $33.89K $17.31K
YoY Change 95.78%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $11.88K $33.89K $17.31K
YoY Change 95.78%
Operating Profit -$33.89K -$17.31K
YoY Change 95.81%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$11.88K -$33.89K -$17.31K
YoY Change 95.78%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.88K -$33.89K -$17.31K
YoY Change 95.78%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$230.80
COMMON SHARES
Basic Shares Outstanding 225.0M shares 225.0M shares 75.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.00 $70.00 $0.00
YoY Change
Cash & Equivalents $68.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $68.00 $70.00 $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $68.00 $70.00 $0.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $68.00 $70.00 $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.83K $22.83K $31.99K
YoY Change 131.2% -28.63%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $14.42K $14.42K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.56K $39.56K $34.29K
YoY Change 15.35% 15.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $39.56K $39.56K $34.29K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $39.56K $39.56K $34.29K
YoY Change 15.35% 15.37%
SHAREHOLDERS EQUITY
Retained Earnings -$114.2K
YoY Change 42.21%
Common Stock $22.50K
YoY Change 200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$39.49K -$39.49K -$34.29K
YoY Change
Total Liabilities & Shareholders Equity $68.00 $70.00 $0.00
YoY Change

Cashflow Statement

Concept 2022 Q3 2022 2021
OPERATING ACTIVITIES
Net Income -$11.88K -$33.89K -$17.31K
YoY Change 95.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$14.46K -$43.05K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.43K $43.12K
YoY Change
NET CHANGE
Cash From Operating Activities -14.46K -$43.05K
Cash From Investing Activities
Cash From Financing Activities 14.43K $43.12K
Net Change In Cash -30.00 $68.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$14.46K -$43.05K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Liverpool
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
usd
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001624140
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2021Q3 us-gaap Assets Current
AssetsCurrent
usd
CY2021Q3 us-gaap Assets
Assets
usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
usd
CY2021Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
usd
CY2021 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
usd
CY2021 us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2021 us-gaap Interest Paid
InterestPaid
usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-56293
CY2022 dei Entity Registrant Name
EntityRegistrantName
Nine Alliance Science & Technology Group
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
35-2515740
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
7325 Oswego Road
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
13090
CY2022 dei City Area Code
CityAreaCode
(315)
CY2022 dei Local Phone Number
LocalPhoneNumber
451-7515
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
25000000 usd
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
225000000 shares
CY2022 dei Auditor Name
AuditorName
Gries & Associates, LLC
CY2022 dei Auditor Location
AuditorLocation
Denver, CO
CY2022 dei Auditor Firm
AuditorFirmId
6778
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
68 usd
CY2022Q3 us-gaap Assets
Assets
68 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15830 usd
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6847 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
7000 usd
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
7370 usd
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
17773 usd
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2303 usd
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2303 usd
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
14424 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39557 usd
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
34293 usd
CY2022Q3 us-gaap Liabilities
Liabilities
39557 usd
CY2021Q3 us-gaap Liabilities
Liabilities
34293 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
225000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75000000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
22500 usd
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7500 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52194 usd
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
38500 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114183 usd
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80293 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-39489 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-34293 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6636 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2151 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
27254 usd
CY2021 us-gaap Professional Fees
ProfessionalFees
15157 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
33890 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
17308 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-33890 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-17308 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-33890 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-17308 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
225000000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75000000 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-18985 usd
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2000 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-17308 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-34293 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28694 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-33890 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-39489 usd
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
33890 usd
CY2021 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
17308 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8983 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3675 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-18143 usd
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
3250 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43050 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17733 usd
CY2022 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
28694 usd
CY2022 us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
14424 usd
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
17733 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43118 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17733 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68 usd
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_zxl1AM2BSO81" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">NOTE 1 – NATURE OF OPERATIONS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Nine Alliance Science and Technology Group (the “Company”) was incorporated as Paramount Supply Inc. and established under the Corporation Laws of the State of Nevada on September 12, 2014. On September 29, 2017, the Company filed a Certificate of Amendment changing the name from “Paramount Supply Inc.” to “Nine Alliance Science and Technology Group”. The Company was formed for the purpose of marketing and distributing ladies fashion handbags. At the end of 2017 the Company became dormant and ceased all business operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 27, 2020, a motion and application was made to appoint a Custodian of the Company based on prior management abandoning its responsibilities to continue making filings at the Nevada Secretary of State’s office and for failing to hold a shareholders’ meeting in over 3 years and otherwise failing to keep current in its obligations to the Company.  Upon motion and application to the District Court, Clark County Nevada, the Court granted the request for Custodian for the Company (“Custodian”).   Upon granting the motion, the Court issued an Order acknowledging that the Custodian has performed all of the duties that had been required of it and the management of the Company will revert exclusively to the officers and directors appointed by the Custodian. In the Revival of the Company, Investment Reserves Series, as the Custodian of the Company, appointed Joseph Passalaqua as CEO, CFO and Secretary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zgtaUiTTzIXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2.2 Use of Estimates and Assumptions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Due to the limited level of operations, the Company has not had to make material assumptions or estimates other than the assumption that the Company is a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
75000000 shares
CY2021Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
300000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
2000 usd
CY2020Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
70000000 shares
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
14424 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
7000 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
114183 usd
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
80293 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.21 pure
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
23873 usd
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
16862 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-23873 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-16862 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
39789 usd
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
28103 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39789 usd
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28103 usd
CY2022Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
80293 usd

Files In Submission

Name View Source Status
0001017386-23-000022-index-headers.html Edgar Link pending
0001017386-23-000022-index.html Edgar Link pending
0001017386-23-000022.txt Edgar Link pending
0001017386-23-000022-xbrl.zip Edgar Link pending
adfdress_001.jpg Edgar Link pending
adfdress_002.jpg Edgar Link pending
exhibit_23-1.htm Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
jmkj-20220930.xsd Edgar Link pending
jmkj2022sept30-10k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
jmkj-20220930_cal.xml Edgar Link unprocessable
jmkj-20220930_def.xml Edgar Link unprocessable
jmkj-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
jmkj-20220930_lab.xml Edgar Link unprocessable
jmkj2022sept30-10k_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending